Mustang Bio, Inc.
MBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.37
KIRA · Stoqly’s AI analyst, in plain words
- Mustang Bio, Inc. lost $1.9M in fiscal 2025.
Market cap
$2.5M
P/E
—
Revenue
—
Net income
−$1.9M
Free cash flow
—
Operating margin
—
Mustang Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$1.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Mustang Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- MUSTANG BIO, INC.
- CIK
- 0001680048
Mustang Bio, Inc. · MBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$66.4M | −$77.5M | −$51.6M | −$15.8M | −$1.9M |
| Diluted EPS | −$0.76 | −$10.09 | −$299.95 | −$38.57 | −$0.39 |
| Cash | |||||
| Cash from operations | −$53.7M | −$65.1M | −$49.5M | −$11.4M | −$5.3M |
| Capital expenditure | $4.0M | $2.7M | $0.1M | $0.0M | — |
| Free cash flow | −$57.7M | −$67.8M | −$49.5M | −$11.4M | — |
| Share count change | 67.1% | −91.3% | −97.8% | 254.5% | 705.0% |
| Debt and strength | |||||
| Cash and short-term investments | $110M | $75.7M | $6.2M | $6.8M | $17.3M |
| Shareholders' equity | $112M | $46.3M | $0.1M | −$3.9M | $9.5M |
| Current ratio | 10.3x | 5.2x | 0.7x | 0.7x | 2.2x |
| Interest coverage | −4,448.2x | −22.7x | −12.0x | −3,249.0x | — |
| Returns and quality | |||||
| Return on equity | −63.0% | −97.7% | −222.4% | — | −67.9% |
| Return on tangible equity | −59.0% | −167.5% | −41,952.8% | — | −20.2% |
| Altman Z'' | 4.4 | −11.6 | −90.1 | −153.8 | −69.9 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mustang Bio, Inc. · MBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.37 a share, the company is worth $2.5M.
Source: SEC EDGAR XBRL filings (CIK 0001680048). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.